

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2020

Vol. 48, No. 9

CONTENTS

MINIREVIEWS

The Role of Sulfotransferases in Liver Diseases. *Yang Xie and Wen Xie* **742**

Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer. *Jiaqi Wang, Lushan Yu, Huidi Jiang, Xiaoli Zheng, and Su Zeng* **759**

ARTICLES

Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics. *Olena Anoshchenko, Bhagwat Prasad, Naveen K. Neradugomma, Joanne Wang, Qingcheng Mao, and Jashvant D. Unadkat* . . **735**

Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics. *Takayuki Taguchi, Yusuke Masuo, Azusa Futatsugi, and Yukio Kato* **750**

Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models. *Makiko Yamada, Tomoko Ishizuka, Shin-ichi Inoue, Veronika Rozehnal, Thomas Fischer, and Daisuke Sugiyama* **769**

Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes. *Hugues Chanteux, Maria Rosa, Claude Delatour, Johan Nicolai, Eric Gillent, Sylvie Dell'Aiera, and Anna-Lena Ungell* . **778**

Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice. *Robert S. Jones, Donna Ruszaj, Mark D. Parker, and Marilyn E. Morris* . **788**

Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer. *P. Kellie Turner, Stephen D. Hall, Sonya C. Chapman, Jessica L. Rehmel, Jane E. Royalty, Yingying Guo, and Palaniappan Kulanthaivel* . . . **796**

Simplifying the Execution of HepatoPac MetID Experiments: Metabolite Profile and Intrinsic Clearance Comparisons. *T. Eric Ballard, N. Kratochwil, Loretta M. Cox, Mark A. Moen, F. Klammers, A. Ekiciler, A. Goetschi, and I. Walter* **804**

Physiologically Based Pharmacokinetics of Dexamethasone in Rats. *Dawei Song, Le Sun, Debra C. DuBois, Richard R. Almon, Shengnan Meng, and William J. Jusko* **811**

Bioactivation of α,β -Unsaturated Carboxylic Acids Through Acyl Glucuronidation. *Teresa Mulder, Sudheer Bobba, Kevin Johnson, Jessica M. Grandner, Wei Wang, Chenghong Zhang, Jingwei Cai, Edna F. Choo, S. Cyrus Khojasteh, and Donglu Zhang* **819**

Dexamethasone-Induced Liver Enlargement Is Related to PXR/YAP Activation and Lipid Accumulation but Not Hepatocyte Proliferation. *Tingying Jiao, Xinpeng Yao, Yingyuan Zhao, Yanying Zhou, Yue Gao, Shicheng Fan, Panpan Chen, Xuan Li, Yiming Jiang, Xiao Yang, Frank J. Gonzalez, Min Huang, and Huichang Bi* **830**

ERRATUM

Correction to "Dexamethasone-Induced Liver Enlargement Is Related to PXR/YAP Activation and Lipid Accumulation but Not Hepatocyte Proliferation". **840**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The methylation status of DME genes contributes to cancer progression and chemoresistance. See the article by Wang et al. ([dx.doi.org/10.1124/dmd.120.000008](https://doi.org/10.1124/dmd.120.000008)).